Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: A 52-week, randomized, double-blind, active-controlled, parallel-group study

E. Bosi, G. C. Ellis, C. A. Wilson, P. R. Fleck

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: A 52-week, randomized, double-blind, active-controlled, parallel-group study'. Together they form a unique fingerprint.

Medicine & Life Sciences